# Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Study · id `cardio:ct-nct07613099` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07613099](<https://clinicaltrials.gov/study/NCT07613099>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07613099

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

## Technical summary

Registry record NCT07613099. Non-randomized; no masking; primary purpose diagnostic. Start 2026-09-18 (actual); primary completion 2031-05-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT07613099, source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)
- Started: 2026-09-18 (actual) (ClinicalTrials.gov record NCT07613099, source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2031-05-26 (anticipated) (ClinicalTrials.gov record NCT07613099, source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)
- Completion: 2033-05-26 (anticipated) (ClinicalTrials.gov record NCT07613099, source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07613099, source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07613099-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
- Condition: Allogeneic Stem Cell Transplantation
- Condition: Lung Allograft Transplantation
- Condition: Interstitial Lung Disease
- Condition: Acute Lung Injury
- Condition: Pulmonary Arterial Hypertension
- Condition: Cardiovascular Diseases
- Intervention (Drug): \[18F\]FAPI-74
- Intervention (Diagnostic test): 18F-FAPI-74 PET/CT Imaging
- Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- Lead sponsor class: NIH

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: d08c2dced2e60a06396e38785415f8d6e01041056042d346e96026c91a7a8e1b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
